Altabax, Altargo(retapamulin)
Altabax, Altargo (retapamulin) is a small molecule pharmaceutical. Retapamulin was first approved as Altabax on 2007-04-12. It is used to treat bacterial infections and impetigo in the USA. It has been approved in Europe to treat impetigo and staphylococcal skin infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| altabax | New Drug Application | 2010-09-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| impetigo | EFO_1000714 | D007169 | L01 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 1 | 1 | 3 | 1 | 2 | 8 |
| Infectious skin diseases | D012874 | — | — | 1 | — | 3 | 1 | 2 | 7 |
| Bacterial skin diseases | D017192 | — | — | 1 | — | 3 | 1 | 2 | 7 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | 1 | — | 3 | 1 | 2 | 7 |
| Impetigo | D007169 | EFO_1000714 | L01 | — | — | 4 | 1 | 1 | 6 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | 1 | 1 | 2 | — | 4 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | — | — | 3 | 1 | 4 |
| Staphylococcal infections | D013203 | — | A49.01 | — | 1 | — | 2 | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 3 | — | 3 |
| Communicable diseases | D003141 | — | — | — | — | — | 2 | — | 2 |
Show 6 more
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Orthopedic procedures | D019637 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Retapamulin |
| INN | retapamulin |
| Description | Retapamulin is a carbotricyclic compound, a carboxylic ester and a cyclic ketone. |
| Classification | Small molecule |
| Drug class | antibacterials, pleuromulin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2C[C@@H]3CC[C@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 224452-66-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1658 |
| ChEBI ID | — |
| PubChem CID | 6918462 |
| DrugBank | DB01256 |
| UNII ID | 4MG6O8991R (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Retapamulin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 642 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
712 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use